CN114652730A - Use of mifepristone for intervention and treatment of nicotine addiction - Google Patents
Use of mifepristone for intervention and treatment of nicotine addiction Download PDFInfo
- Publication number
- CN114652730A CN114652730A CN202111491219.2A CN202111491219A CN114652730A CN 114652730 A CN114652730 A CN 114652730A CN 202111491219 A CN202111491219 A CN 202111491219A CN 114652730 A CN114652730 A CN 114652730A
- Authority
- CN
- China
- Prior art keywords
- nicotine
- mifepristone
- addiction
- administration
- dependence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003248 mifepristone Drugs 0.000 title claims abstract description 75
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 title claims abstract description 75
- 206010057852 Nicotine dependence Diseases 0.000 title claims abstract description 41
- 208000025569 Tobacco Use disease Diseases 0.000 title claims abstract description 40
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 63
- 229960002715 nicotine Drugs 0.000 claims abstract description 63
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 27
- 241000208125 Nicotiana Species 0.000 claims abstract description 11
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 11
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 9
- 235000019505 tobacco product Nutrition 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000000391 smoking effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 206010012335 Dependence Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 4
- 201000009032 substance abuse Diseases 0.000 claims description 4
- 231100000736 substance abuse Toxicity 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 claims description 4
- 229950008166 valnemulin Drugs 0.000 claims description 4
- 229960001058 bupropion Drugs 0.000 claims description 3
- 239000003571 electronic cigarette Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 235000019506 cigar Nutrition 0.000 claims description 2
- 235000019504 cigarettes Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 51
- 238000001990 intravenous administration Methods 0.000 description 21
- 239000002904 solvent Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 235000019788 craving Nutrition 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940059344 chantix Drugs 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000036279 refractory period Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- BDTXJBWOCIFUMR-UHFFFAOYSA-N 230615-59-5 Chemical compound C1N(C(=O)C(F)(F)F)CC2CC1C1=C2C=C([N+](=O)[O-])C([N+]([O-])=O)=C1 BDTXJBWOCIFUMR-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940018503 zyban Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Abstract
The invention discloses application of mifepristone in intervention and treatment of nicotine addiction. In particular to an application of mifepristone in preparing a medicine for reducing nicotine addiction, dependence degree or reward property, an application in preparing a medicine for relieving nicotine withdrawal symptoms and an application in preparing a medicine for reducing the usage amount of nicotine-containing tobacco. Also disclosed is a tobacco product comprising mifepristone. The invention proves that the mifepristone has the effects of reducing nicotine addiction, dependence degree or reward property, relieving nicotine withdrawal symptoms and reducing active intake and intake frequency of nicotine. Mifepristone is a medicine which is on the market for many years, has good druggability, small toxic and side effects and very low cost, and is expected to be developed into a nicotine withdrawal medicine or an auxiliary medicament.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of mifepristone in intervention and treatment of nicotine addiction.
Background
Nicotine is a main addictive substance in tobacco, and at present, effective medicines for treating nicotine addiction are seriously lacked clinically. At present, three smoking cessation therapies are used internationally. The first is nicotine replacement therapy, which includes nicotine sugar and patches. The craving for tobacco during smoking cessation is reduced mainly by maintaining nicotine levels in the body by means of slow release of nicotine. The second is the administration of Vannicline (Vareniline, trade name Chantix). This is a partial agonist of nicotinic acetylcholine receptor alpha 4 beta 2. The alpha 4 beta 2 receptor is abundantly expressed in the dopaminergic nervous system and plays an important role in rewarding the nicotine. The third is the administration of bupropion (trade name Zyban), a drug used in the clinical treatment of depression and approved by the FDA to help quit smoking.
The best drug currently used to treat nicotine addiction is valnemulin (trade name, chantix, free) invented by pfeir. The major side effects of valnemulin include epilepsy, cardiovascular problems, allergic reactions and severe skin reactions. In addition, chantix is expensive, costing 1800 dollars per 12 week in the united states; a 24 week treatment period costs $ 3600. However, mifepristone used clinically at present has small side effect and low price.
Disclosure of Invention
Mifepristone is a clinically common potent antiprogestogen that acts by binding to progesterone and glucocorticoid receptors in the body. The key point of the invention is to adopt the mifepristone strategy to help the smoking population and the electronic cigarette using population to treat nicotine addiction and help quit smoking.
One aspect of the invention provides the use of mifepristone in the preparation of a medicament for reducing nicotine addiction, dependence or reward.
In another aspect of the invention, the invention provides an application of mifepristone in preparing a medicament for relieving nicotine withdrawal symptoms.
In another aspect, the invention provides the use of mifepristone in the preparation of a medicament for reducing the amount of nicotine-containing tobacco used.
In a further aspect of the invention there is provided a pharmaceutical composition for treating nicotine dependence or addiction, tobacco dependence or addiction, reducing nicotine withdrawal symptoms or aiding in the cessation or reduction of tobacco use or substance abuse or behavioral dependence, said pharmaceutical composition having mifepristone as the active ingredient.
Further, in the pharmaceutical composition, mifepristone is used as the only active ingredient.
Further, the pharmaceutical composition also comprises other medicines for treating nicotine addiction. Preferably, the other nicotine addiction treating drug is selected from the group consisting of valnemulin, bupropion.
Further, the pharmaceutical composition is in the form of injection, oral preparation, transdermal preparation or atomized preparation.
In a further aspect of the invention there is provided a smoking article comprising mifepristone.
Further, the tobacco product may or may not comprise nicotine.
Further, the tobacco product is selected from any one of cigarettes, tobacco pipes, cigars, electronic cigarettes and tobacco leaves.
In yet another aspect, the invention provides a method of reducing nicotine dependence or addiction, tobacco dependence or addiction, reducing nicotine withdrawal symptoms, or aiding in the cessation or reduction of tobacco use or substance abuse or behavioral dependence in a subject,
the method comprises the step of administering mifepristone to the subject.
Further, the subject is a nicotine addicted subject or a subject having a habit of smoking a nicotine-containing product.
Further, the method of administering mifepristone to a subject includes administration by oral, injection, aerosol inhalation, or transdermal administration.
Advantageous effects
The invention proves that the mifepristone has the effects of reducing nicotine addiction, dependence degree or reward property, relieving nicotine withdrawal symptoms and reducing active intake and intake frequency of nicotine.
The experimental results of the invention prove that the mifepristone has very quick and efficient action and can achieve very obvious effect only by once administration for one hour.
Mifepristone is a medicine which has been on the market for many years, has good drugability, small toxic and side effects and very low cost, and is expected to be developed into a nicotine withdrawal medicine or an auxiliary medicament.
Drawings
Figure 1 is a graph of the results of example 2 mifepristone significantly reducing the number of nicotine self-administrations in rats. The ordinate represents the number of self-administrations per hour in the rat. Fr (fixed ratio) is 5 and to (time out) is 20s, i.e. one intravenous injection is obtained for each 5 pedal times of the rat, and the refractory period is 20 seconds thereafter. After the rats in the nicotine group completed treading 5 times, one nicotine intravenous injection was obtained, and the nicotine dosage used was 0.12mg/kg per injection. And after the rats in the normal saline group complete treading for 5 times, obtaining one normal saline intravenous injection. It can be seen from the figure that the intraperitoneal injection of 60mg/kg mifepristone significantly reduces the self-administration frequency of nicotine compared with the solvent injection (solvent vs mifepristone, 8.3 + -1.7 vs 5.1 + -0.8), but does not affect the self-administration frequency of the normal saline group (2.1 + -0.8 vs 2.0 + -0.5). At least 6 rats per group. P < 0.05; student Paired T test.
Figure 2 is a graph of the results of example 3 mifepristone significantly reducing nicotine cravings in nicotine addicted rats. The extent of nicotine craving in rats was assessed by testing the time it took for the rats to autonomously obtain the first (left panel) and second (right panel) intravenous self-administration after the experiment began on the day of the experiment, with less time being more craving for nicotine. Compared with the saline rats, the nicotine rats have shorter time for self-administration of the first and second intravenous drugs and are more urgent. Mifepristone significantly reduced nicotine cravings in rats, reflecting an increased tendency to acquire the first intravenous self-administration and a significantly increased time to the second intravenous self-administration in rats. Mifepristone has no significant effect on the urgency of intravenous self-administration of physiological saline. Time of first intravenous self-administration: (a) a physiological saline group (solvent vs mifepristone, 1122 + -331 vs745 + -346 s); (b) nicotine from the group administered (solvent vs mifepristone, 81 ± 23vs 174 ± 53 s). Time of second intravenous self-administration: (a) a normal saline group (solvent vs mifepristone, 1620 + -872 vs 1275 + -456 s); (b) nicotine from the group of doses (solvent vs mifepristone, 188 ± 24vs 372 ± 66 s). P < 0.05; student Paired T test.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention more comprehensible, specific embodiments thereof are described in detail below, but the present invention is not to be construed as being limited to the implementable range thereof.
Example 1 animal model for establishing nicotine addiction and control group
An animal model of model nicotine addiction is established by adopting a nicotine intravenous self-administration mode. Animal model rats were selected and a catheter was previously implanted in the jugular vein of the rat up to the heart, the other end of the catheter being connected to a syringe pump containing a nicotine solution. Animals underwent nicotine self-administration training after recovery from surgery in a control box with two pedals, where depression of one of the pedals activates a nicotine syringe pump, causing intravenous infusion of nicotine. The FR (fixed ratio) of the device is 5, the TO (time out) is 20s, i.e. one intravenous injection is obtained when the rat completes the pedal times for 5 times, and the later 20s is a refractory period, i.e. the intravenous injection cannot be caused even if the pedal is pressed again within 20s after the 5 pedal times are completed. After each training session, rats in the nicotine addiction model group will undergo intravenous self-administration injections of nicotine within a short period of time
Rats were trained continuously for at least 2 weeks. After the self-administration times per day are stabilized (the self-administration times change by no more than 20 percent in three consecutive days), the model is successfully built, an animal model (nicotine self-administration group) of nicotine addiction is obtained, and subsequent experiments are carried out.
Meanwhile, by the same method, only nicotine was replaced with physiological saline to obtain a physiological saline self-administration group model rat (control group), the self-administration frequency of the physiological saline self-administration group rat was much lower than that of the nicotine addiction model rat, and intravenous self-administration injection of the physiological saline was started after the experiment started for a long time.
Example 2 Effect of mifepristone on the number of self-administrations of nicotine
For nicotine self-administration group and self-administration group rats successfully modeled, a study experiment of the influence of mifepristone on the self-administration times was carried out, and 6 rats per group. The test mode used was an intragroup cross-control experiment.
The first test was carried out by intraperitoneally injecting mifepristone solution into half (3 rats) of the animals in each group and solvent into the other half (3 rats) 1 hour before the start of the administration test, and the administration dose of mifepristone was 60 mg/kg. The number of self-administrations per hour in the rats in the self-administration experiment was then recorded.
No drug intervention was given within 3 days after the first trial, and a second test was performed after the rats had returned to pre-dose levels from the number of self-doses.
The second test is that the first test of each group of test animals is to inject the mifepristone solution into 3 rats in the abdominal cavity 1 hour before the beginning of the administration test, and the first test is to inject the mifepristone solution into 3 rats in the abdominal cavity, wherein the administration dose of the mifepristone is 60 mg/kg. The number of self-administrations per hour in the rats in the self-administration experiment was then recorded.
The results of the statistical analysis are shown in FIG. 1. The test results show that the rats in the normal saline self-administration group have very low self-administration times because the normal saline is not addicted, and the rats which are administrated with the solvent have no significant difference in the administration times with the rats which are administrated with the mifepristone. That is, mifepristone does not affect the behavior of healthy, non-addictive subjects. In the nicotine self-administration group, the self-administration frequency of the rats with mifepristone and the rats with solvent has a significant difference (the solvent vs mifepristone, 8.3 +/-1.7 vs 5.1 +/-0.8). The intravenous self-administration times of the rats in the nicotine self-administration group can be obviously reduced after the mifepristone is administrated. Namely, the compound can reduce the dependence of rats with nicotine addiction on nicotine, reduce the active intake of nicotine-addicted subjects and intake dosage. Moreover, the mifepristone has obvious nicotine inhibition effect, and can achieve very obvious effect only by one-time administration. Moreover, mifepristone is a medicament which has been on the market for decades, has good pharmacy and low toxic and side effects, and has great potential to be developed into a smoking cessation medicament.
Example 3 Effect of mifepristone on Nicotine self-administration time
For nicotine self-administration group and self-administration group rats successfully modeled, a study experiment of the influence of mifepristone on the self-administration times was carried out, and 6 rats per group.
Half of the animals in each group (3 rats) were intraperitoneally injected with mifepristone solution and the other half (3 rats) with solvent 1 hour before the start of the administration experiment, and the administration dose of mifepristone was 60 mg/kg. The time at which the rats autonomously acquired the first and second intravenous self-administration per hour in the self-administration experiment was then recorded. According to the time of the first administration and the second administration, the craving degree of the nicotine-addicted rat to the nicotine can be judged, and the shorter the time, the higher the craving degree.
Statistical analysis the results are shown in figure 2, and mifepristone has no significant effect on the exigencies of physiological saline intravenous self-administration.
Time of first intravenous self-administration: (a) the physiological saline self-administration group has no significant difference between the group to which the solvent is administered and the group to which the mifepristone solution is administered (the solvent vs mifepristone, 1122 +/-331 vs745 +/-346 s), (b) the nicotine self-administration group has significant difference between the group to which the solvent is administered and the group to which the mifepristone solution is administered, and the time for the first intravenous self-administration of rats injected with the mifepristone solution is longer, which indicates that the mifepristone can reduce the craving of nicotine for nicotine addiction subjects. (solvent vs mifepristone, 81 + -23 vs 174 + -53 s).
Time of second intravenous self-administration: (a) the physiological saline self-administration group has no significant difference between the group to which the solvent is administered and the group to which the mifepristone solution is administered (the solvent vs mifepristone, 1620 +/-872 vs 1275 +/-456 s), (b) the nicotine self-administration group has significant difference between the group to which the solvent is administered and the group to which the mifepristone solution is administered, and the rats injected with the mifepristone solution have longer first intravenous self-administration time, which indicates that the mifepristone can reduce the craving of nicotine for nicotine addiction subjects. (solvent vs mifepristone, 188 + -24 vs 372 + -66 s). P < 0.05; student Paired T test.
Compared with the saline group rats, the nicotine group rats autonomously obtain the first and second intravenous self-administration in shorter time and are more urgent. Mifepristone significantly reduced nicotine cravings in rats, reflecting an increased tendency to acquire the first intravenous self-administration and a significantly increased time to the second intravenous self-administration in rats.
In conclusion, by adopting a rat nicotine vein self-administration addiction model for simulating the self-smoking of the smoking population, the subcutaneous injection of 60mg/kg mifepristone can obviously reduce the times of the rat nicotine self-administration and the craving degree of nicotine; while the injection of mifepristone at the same dose had no effect on the number of self-administrations of physiological saline. Experimental data show that the mifepristone has the effects of intervening nicotine addiction and craving and has the potential clinical efficacy of treating nicotine addiction.
Claims (10)
1. Use of mifepristone for the preparation of a medicament for reducing nicotine addiction, dependence or reward.
2. Use of mifepristone in preparing medicine for relieving nicotine withdrawal symptom is provided.
3. Use of mifepristone in the manufacture of a medicament for reducing the amount of nicotine-containing tobacco used.
4. A pharmaceutical composition for treating nicotine dependence or addiction, tobacco dependence or addiction, reducing nicotine withdrawal symptoms or aiding in the cessation or reduction of tobacco use or substance abuse or behavioral dependence, wherein mifepristone is the active ingredient in said pharmaceutical composition;
preferably, mifepristone is used as the only active ingredient in the pharmaceutical composition.
5. The pharmaceutical composition of claim 4, further comprising a pharmaceutically acceptable carrier in combination with other nicotine addiction treatment drugs;
preferably, the other nicotine addiction treating drug is selected from the group consisting of valnemulin, bupropion.
6. The pharmaceutical composition according to claim 4 or 5, wherein the pharmaceutical composition is formulated in the form of an injection, an oral formulation, a transdermal formulation or an aerosolized formulation.
7. A smoking article characterized in that said smoking article comprises mifepristone.
8. The smoking article of claim 7, wherein said smoking article comprises nicotine or comprises no nicotine.
9. The tobacco product of claim 7, wherein the tobacco product is selected from any one of a cigarette, a pipe, a cigar, an electronic cigarette, and a leaf.
10. Methods of reducing nicotine dependence or addiction, tobacco dependence or addiction, reducing nicotine withdrawal symptoms, or aiding in the cessation or reduction of tobacco use or substance abuse or behavioral dependence in a subject,
the method comprises the step of administering mifepristone to the subject;
preferably, the subject is a nicotine addicted subject or a subject having a habit of smoking a nicotine-containing product;
preferably, the method of administering mifepristone to a subject comprises administration by oral, injection, aerosol inhalation or transdermal administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111491219.2A CN114652730A (en) | 2021-12-08 | 2021-12-08 | Use of mifepristone for intervention and treatment of nicotine addiction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111491219.2A CN114652730A (en) | 2021-12-08 | 2021-12-08 | Use of mifepristone for intervention and treatment of nicotine addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114652730A true CN114652730A (en) | 2022-06-24 |
Family
ID=82026240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111491219.2A Pending CN114652730A (en) | 2021-12-08 | 2021-12-08 | Use of mifepristone for intervention and treatment of nicotine addiction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114652730A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998026785A1 (en) * | 1996-12-19 | 1998-06-25 | Hoechst Marion Roussel | Use of mifepristone for the treatment of psychoses and addictive behaviours |
| US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| US20150018414A1 (en) * | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International lll Limited | Promotion of Smoking Cessation |
| US20170051007A1 (en) * | 2015-08-03 | 2017-02-23 | Pop Test Oncology Limited Liability Company | Pharmaceutical compositions and methods |
| WO2018067520A2 (en) * | 2016-10-04 | 2018-04-12 | Pop Test Oncology Llc | Therapeutic agents and methods: |
| CN108025008A (en) * | 2015-06-22 | 2018-05-11 | 安比拉神经疗法公司 | The composition and method of obstacle, habituation and mental disease are used for therapeutic substance |
-
2021
- 2021-12-08 CN CN202111491219.2A patent/CN114652730A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998026785A1 (en) * | 1996-12-19 | 1998-06-25 | Hoechst Marion Roussel | Use of mifepristone for the treatment of psychoses and addictive behaviours |
| US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| US20150018414A1 (en) * | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International lll Limited | Promotion of Smoking Cessation |
| CN108025008A (en) * | 2015-06-22 | 2018-05-11 | 安比拉神经疗法公司 | The composition and method of obstacle, habituation and mental disease are used for therapeutic substance |
| US20170051007A1 (en) * | 2015-08-03 | 2017-02-23 | Pop Test Oncology Limited Liability Company | Pharmaceutical compositions and methods |
| WO2018067520A2 (en) * | 2016-10-04 | 2018-04-12 | Pop Test Oncology Llc | Therapeutic agents and methods: |
Non-Patent Citations (1)
| Title |
|---|
| 牛海晨;郑英伟;程嘉艺;马原野;: "米非司酮(RU486)对吗啡成瘾后新颖环境探究活动量的影响", 现代生物医学进展 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henningfield et al. | Nicotine delivery kinetics and abuse liability. | |
| US6358060B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| US6541478B1 (en) | Smoking cessation treatments using naltrexone and related compounds | |
| Rose | Nicotine and nonnicotine factors in cigarette addiction | |
| RU2262352C2 (en) | Applying agonists of gamma-aminobutyric acid receptors of b-type and their pharmaceutically acceptable derivatives in treatment of nicotine dependence | |
| JP4173538B2 (en) | Nasal and ophthalmic administration of ketamine for pain management and detoxification | |
| CN114652730A (en) | Use of mifepristone for intervention and treatment of nicotine addiction | |
| Pajai et al. | Pharmacotherapy in tobacco cessation: a narrative review | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| RU2445971C2 (en) | Aqueous extract of tobacco leaves and use thereof in treating dependence | |
| Willette et al. | Acute and chronic interactive treatments of serotonin 5HT2C and dopamine D1 receptor systems for decreasing nicotine self-administration in female rats | |
| US6630449B2 (en) | Method for reducing the effect of nicotine addiction and dependancy | |
| JP2009536183A5 (en) | ||
| CN112569237A (en) | Application of combination or compound of imatinib and derivatives thereof and nicotine or analogues thereof in preventing and treating nicotine addiction and relapse | |
| RU2146942C1 (en) | Method of treatment of tobacco smoking | |
| US20220079982A1 (en) | Formulation for treating tobacco or psychotrope withdrawal symptoms | |
| Clarke | Recent advances in understanding the actions of nicotine in the central nervous system | |
| EP1408968B1 (en) | Receptor-adapted nicotine withdrawal by a combination of atropine, scopolamine, clonidine | |
| Yadav et al. | TOBACCO CESSATION THROUGH NICOTINE REPLACEMENT THERAPY | |
| Schwienteck et al. | Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys. | |
| Milhorn et al. | Opioids | |
| Naqvi | The Impact of Nicotine and Social Drinking Behavior and Brain Function | |
| Lo | Concurrent self-administration of alcohol and nicotine in an operant paradigm | |
| Kumar et al. | Nicotine addiction and its Pharmacological effects: A Review | |
| Buchhalter et al. | Nicotine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220624 |